EX-10.7





 Exhibit 10.7 

NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE,
UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

FIRST AMENDMENT TO 

EXCLUSIVE DISTRIBUTION AGREEMENT 

This First Amendment (this “Amendment”) to Exclusive Distribution Agreement is entered into as of
September 27, 2011 (the “Effective Date”), by and between Zimmer Dental Inc., a Delaware corporation (“Zimmer”), and RTI Biologics, Inc., a Delaware corporation
(“RTI”). Unless otherwise defined herein, capitalized terms shall have the meanings given to them in the Agreement (as defined below). 

Recitals 

A.    Zimmer and RTI entered into an Exclusive Distribution Agreement on September 30, 2010 (the
“Agreement”). 
 B.    Zimmer and RTI desire to amend the Agreement in accordance
with Section 13.4 of the Agreement. 
 Agreement 

For good and valuable consideration, the receipt and sufficiency of which is acknowledged by the execution and delivery of this Amendment,
Zimmer and RTI agree to amend the Agreement as follows: 
 1.    Amendment to Agreement. Exhibit A to the
Agreement shall be amended to include the following additional Implants: 
  

																			
	 Part
Numbers
US,
LA,
APR,
CAN
	  	 Brand/Product Description
	  	 Transfer
Fee
US/LA/APR/CN
	 	  	
Lead
time
Calendar
Days
	 	  	
Label
Shelf
Life
	 	  	 Minimum
Shelf
Life
Upon
Receipt
	 
		  	Human Bone Allograft	  				  				  				  			
	68800	  	PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 0.5cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 
						
	68801	  	PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 1cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 
						
	68802	  	PUROS CORTICO-CANCELLOUS MIX ø 0.25-1mm, 2cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 
						
	68803	  	PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 0.5cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 
						
	68804	  	PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 1cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 
						
	68805	  	PUROS CORTICO-CANCELLOUS MIX ø 1-2mm, 2cc	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 	  	 	[****]	 


  
 - 1 - 














 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 2.    Development Fee. As consideration for the development of the
Implants set forth in Section 1 above, Zimmer shall pay the amount set forth on Quotation Number 2011016 R3, attached hereto as Annex A. 

3.    Effect on the Agreement. Except as specifically amended above, the Agreement shall remain in full force and
effect and is hereby ratified and confirmed. This Amendment is being effected in accordance with Section 13.4 of the Agreement. 

[Remainder of Page Intentionally Blank] 

  
 - 2 - 














 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its respective
duly authorized representative as of the Effective Date. 
  

			
	RTI BIOLOGICS, INC.
		
	By:	 	/s/ Roger Rose


 
			
		
	Name:	 	Roger Rose


 
			
		
	Title:	 	Executive Vice President


 
			
	
	ZIMMER DENTAL, INC.
		
	By:	 	/s/ Harold Flynn


 
			
		
	Name:	 	Harold Flynn


 
			
		
	Title:	 	President



  
 - 3 - 














 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 Annex A 

Quotation Product Development 

  
 - 4 - 














 NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE
BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST. 

 

 



 

  
 - 5 -